Download PDF
Semin Thromb Hemost 2010; 36(3): 332-342
DOI: 10.1055/s-0030-1253455
© Thieme Medical Publishers

Targeting Antioxidant and Antithrombotic Biotherapeutics to Endothelium

Ronald Carnemolla1 , Vladimir V. Shuvaev1 , Vladimir R. Muzykantov1
  • 1Department of Pharmacology and Program in Targeted Therapeutics of the Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Further Information

Publication History

Publication Date:
20 May 2010 (online)

    Permissions and Reprints

ABSTRACT

The endothelium is one of the key targets for pharmacological interventions in oxidative stress and thrombosis, two conditions that are notoriously difficult to treat due to limited efficacy and precision of action of current drugs. Design of molecular and nano-devices that deliver potent antioxidant and antithrombotic therapeutic enzymes to the endothelium holds promise to improve the potency, localization, timing, specificity, safety, and mechanistic precision of these interventions. In particular, cell adhesion molecules expressed on the surface of resting and pathologically altered endothelial cells can be used for drug delivery to the endothelial surface (preferable for thrombolytics) and into intracellular compartments (preferable for antioxidants). Drug delivery platforms including protein conjugates, recombinant fusion constructs, and stealth polymer carriers designed to target these drugs to endothelium are reviewed in this article.

KEYWORDS

Targeted therapeutics - nanocarriers - drug delivery - antioxidants - thromboprophylaxis - endothelium

REFERENCES

  • 1 Muzykantov V R. Biomedical aspects of targeted delivery of drugs to pulmonary endothelium.  Expert Opin Drug Deliv. 2005;  2(5) 909-926
    CrossrefPubMedGoogle Scholar
  • 2 Hajitou A, Trepel M, Lilley C E et al.. A hybrid vector for ligand-directed tumor targeting and molecular imaging.  Cell. 2006;  125(2) 385-398
    CrossrefPubMedGoogle Scholar
  • 3 Durr E, Yu J, Krasinska K M et al.. Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture.  Nat Biotechnol. 2004;  22(8) 985-992
    CrossrefPubMedGoogle Scholar
  • 4 Oh P, Li Y, Yu J et al.. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy.  Nature. 2004;  429(6992) 629-635
    CrossrefPubMedGoogle Scholar
  • 5 Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display.  J Clin Invest. 1998;  102(2) 430-437
    CrossrefPubMedGoogle Scholar
  • 6 Ghitescu L, Jacobson B S, Crine P. A novel, 85 kDa endothelial antigen differentiates plasma membrane macrodomains in lung alveolar capillaries.  Endothelium. 1999;  6(3) 241-250
    CrossrefPubMedGoogle Scholar
  • 7 Murciano J C, Harshaw D W, Ghitescu L, Danilov S M, Muzykantov V R. Vascular immunotargeting to endothelial surface in a specific macrodomain in alveolar capillaries.  Am J Respir Crit Care Med. 2001;  164(7) 1295-1302
    PubMedGoogle Scholar
  • 8 Oh P, Borgström P, Witkiewicz H et al.. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung.  Nat Biotechnol. 2007;  25(3) 327-337
    CrossrefPubMedGoogle Scholar
  • 9 Muzykantov V R, Puchnina E A, Atochina E N et al.. Endotoxin reduces specific pulmonary uptake of radiolabeled monoclonal antibody to angiotensin-converting enzyme.  J Nucl Med. 1991;  32(3) 453-460
    PubMedGoogle Scholar
  • 10 Danilov S, Atochina E, Hiemisch H et al.. Interaction of mAb to angiotensin-converting enzyme (ACE) with antigen in vitro and in vivo: antibody targeting to the lung induces ACE antigenic modulation.  Int Immunol. 1994;  6(8) 1153-1160
    CrossrefPubMedGoogle Scholar
  • 11 Danilov S M, Gavrilyuk V D, Franke F E et al.. Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting.  Am J Physiol Lung Cell Mol Physiol. 2001;  280(6) L1335-L1347
    PubMedGoogle Scholar
  • 12 Heitsch H, Brovkovych S, Malinski T, Wiemer G. Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells.  Hypertension. 2001;  37(1) 72-76
    PubMedGoogle Scholar
  • 13 Muzykantov V R, Atochina E N, Kuo A et al.. Endothelial cells internalize monoclonal antibody to angiotensin-converting enzyme.  Am J Physiol. 1996;  270(5 Pt 1) L704-L713
    PubMedGoogle Scholar
  • 14 Danilov S M, Martynov A V, Klibanov A L et al.. Radioimmunoimaging of lung vessels: an approach using indium-111-labeled monoclonal antibody to angiotensin-converting enzyme.  J Nucl Med. 1989;  30(10) 1686-1692
    PubMedGoogle Scholar
  • 15 Balyasnikova I V, Metzger R, Visintine D J et al.. Selective rat lung endothelial targeting with a new set of monoclonal antibodies to angiotensin I-converting enzyme.  Pulm Pharmacol Ther. 2005;  18(4) 251-267
    CrossrefPubMedGoogle Scholar
  • 16 Balyasnikova I V, Sun Z L, Metzger R et al.. Monoclonal antibodies to native mouse angiotensin-converting enzyme (CD143): ACE expression quantification, lung endothelial cell targeting and gene delivery.  Tissue Antigens. 2006;  67(1) 10-29
    CrossrefPubMedGoogle Scholar
  • 17 Muzykantov V R, Danilov S M. Targeting of radiolabeled monoclonal antibody against ACE to the pulmonary endothelium. In: Torchilin V Targeted Delivery of Imaging Agents. Roca Baton, FL; CRC Press 1995: 465-485
    Google Scholar
  • 18 Muzykantov V R, Atochina E N, Ischiropoulos H, Danilov S M, Fisher A B. Immunotargeting of antioxidant enzyme to the pulmonary endothelium.  Proc Natl Acad Sci U S A. 1996;  93(11) 5213-5218
    CrossrefPubMedGoogle Scholar
  • 19 Atochina E N, Balyasnikova I V, Danilov S M, Granger D N, Fisher A B, Muzykantov V R. Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress.  Am J Physiol. 1998;  275(4 Pt 1) L806-L817
    PubMedGoogle Scholar
  • 20 Nowak K, Weih S, Metzger R et al.. Immunotargeting of catalase to lung endothelium via anti-angiotensin-converting enzyme antibodies attenuates ischemia-reperfusion injury of the lung in vivo.  Am J Physiol Lung Cell Mol Physiol. 2007;  293(1) L162-L169
    CrossrefPubMedGoogle Scholar
  • 21 Watanabe K, Lam G, Keresztes R S, Jaffe E A. Lipopolysaccharides decrease angiotensin converting enzyme activity expressed by cultured human endothelial cells.  J Cell Physiol. 1992;  150(2) 433-439
    CrossrefPubMedGoogle Scholar
  • 22 Atochina E N, Hiemisch H H, Muzykantov V R, Danilov S M. Systemic administration of platelet-activating factor in rat reduces specific pulmonary uptake of circulating monoclonal antibody to angiotensin-converting enzyme.  Lung. 1992;  170(6) 349-358
    PubMedGoogle Scholar
  • 23 Scherpereel A, Wiewrodt R, Christofidou-Solomidou M et al.. Cell-selective intracellular delivery of a foreign enzyme to endothelium in vivo using vascular immunotargeting.  FASEB J. 2001;  15(2) 416-426
    CrossrefPubMedGoogle Scholar
  • 24 Danielyan K, Ding B S, Gottstein C, Cines D B, Muzykantov V R. Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema.  J Pharmacol Exp Ther. 2007;  321(3) 947-952
    CrossrefPubMedGoogle Scholar
  • 25 Garnacho C, Dhami R, Simone E et al.. Delivery of acid sphingomyelinase in normal and Niemann-Pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers.  J Pharmacol Exp Ther. 2008;  325(2) 400-408
    CrossrefPubMedGoogle Scholar
  • 26 Muro S, Dziubla T, Qiu W et al.. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1.  J Pharmacol Exp Ther. 2006;  317(3) 1161-1169
    CrossrefPubMedGoogle Scholar
  • 27 Muro S, Muzykantov V R. Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules.  Curr Pharm Des. 2005;  11(18) 2383-2401
    CrossrefPubMedGoogle Scholar
  • 28 Nakada M T, Amin K, Christofidou-Solomidou M et al.. Antibodies against the first Ig-like domain of human platelet endothelial cell adhesion molecule-1 (PECAM-1) that inhibit PECAM-1-dependent homophilic adhesion block in vivo neutrophil recruitment.  J Immunol. 2000;  164(1) 452-462
    PubMedGoogle Scholar
  • 29 Murohara T, Delyani J A, Albelda S M, Lefer A M. Blockade of platelet endothelial cell adhesion molecule-1 protects against myocardial ischemia and reperfusion injury in cats.  J Immunol. 1996;  156(9) 3550-3557
    PubMedGoogle Scholar
  • 30 Kumasaka T, Quinlan W M, Doyle N A et al.. Role of the intercellular adhesion molecule-1(ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice.  J Clin Invest. 1996;  97(10) 2362-2369
    CrossrefPubMedGoogle Scholar
  • 31 Muro S, Wiewrodt R, Thomas A et al.. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1.  J Cell Sci. 2003;  116(Pt 8) 1599-1609
    CrossrefPubMedGoogle Scholar
  • 32 Muzykantov V R, Christofidou-Solomidou M, Balyasnikova I et al.. Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs.  Proc Natl Acad Sci U S A. 1999;  96(5) 2379-2384
    CrossrefPubMedGoogle Scholar
  • 33 Albelda S M. Endothelial and epithelial cell adhesion molecules.  Am J Respir Cell Mol Biol. 1991;  4(3) 195-203
    PubMedGoogle Scholar
  • 34 Wiewrodt R, Thomas A P, Cipelletti L et al.. Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells.  Blood. 2002;  99(3) 912-922
    CrossrefPubMedGoogle Scholar
  • 35 Christofidou-Solomidou M, Pietra G G, Solomides C C et al.. Immunotargeting of glucose oxidase to endothelium in vivo causes oxidative vascular injury in the lungs.  Am J Physiol Lung Cell Mol Physiol. 2000;  278(4) L794-L805
    PubMedGoogle Scholar
  • 36 Scherpereel A, Rome J J, Wiewrodt R et al.. Platelet-endothelial cell adhesion molecule-1-directed immunotargeting to cardiopulmonary vasculature.  J Pharmacol Exp Ther. 2002;  300(3) 777-786
    CrossrefPubMedGoogle Scholar
  • 37 Li S, Tan Y, Viroonchatapan E, Pitt B R, Huang L. Targeted gene delivery to pulmonary endothelium by anti-PECAM antibody.  Am J Physiol Lung Cell Mol Physiol. 2000;  278(3) L504-L511
    PubMedGoogle Scholar
  • 38 Muro S, Cui X, Gajewski C, Murciano J C, Muzykantov V R, Koval M. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress.  Am J Physiol Cell Physiol. 2003;  285(5) C1339-C1347
    CrossrefPubMedGoogle Scholar
  • 39 Almenar-Queralt A, Duperray A, Miles L A, Felez J, Altieri D C. Apical topography and modulation of ICAM-1 expression on activated endothelium.  Am J Pathol. 1995;  147(5) 1278-1288
    PubMedGoogle Scholar
  • 40 Panés J, Perry M A, Anderson D C et al.. Regional differences in constitutive and induced ICAM-1 expression in vivo.  Am J Physiol. 1995;  269(6 Pt 2) H1955-H1964
    PubMedGoogle Scholar
  • 41 Murciano J C, Muro S, Koniaris L et al.. ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface.  Blood. 2003;  101(10) 3977-3984
    CrossrefPubMedGoogle Scholar
  • 42 Beck-Schimmer B, Schimmer R C, Warner R L et al.. Expression of lung vascular and airway ICAM-1 after exposure to bacterial lipopolysaccharide.  Am J Respir Cell Mol Biol. 1997;  17(3) 344-352
    PubMedGoogle Scholar
  • 43 Vaporciyan A A, Mulligan M S, Warren J S, Barton P A, Miyasaka M, Ward P A. Up-regulation of lung vascular ICAM-1 in rats is complement dependent.  J Immunol. 1995;  155(3) 1442-1449
    PubMedGoogle Scholar
  • 44 Sasso D E, Gionfriddo M A, Thrall R S, Syrbu S I, Smilowitz H M, Weiner R E. Biodistribution of indium-111-labeled antibody directed against intercellular adhesion molecule-1.  J Nucl Med. 1996;  37(4) 656-661
    PubMedGoogle Scholar
  • 45 Villanueva F S, Jankowski R J, Klibanov S et al.. Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells.  Circulation. 1998;  98(1) 1-5
    CrossrefPubMedGoogle Scholar
  • 46 Bloemen P G, Henricks P A, van Bloois L et al.. Adhesion molecules: a new target for immunoliposome-mediated drug delivery.  FEBS Lett. 1995;  357(2) 140-144
    CrossrefPubMedGoogle Scholar
  • 47 Kishimoto T K, Rothlein R. Integrins, ICAMs, and selectins: role and regulation of adhesion molecules in neutrophil recruitment to inflammatory sites.  Adv Pharmacol. 1994;  25 117-169
    PubMedGoogle Scholar
  • 48 Springer T A. Adhesion receptors of the immune system.  Nature. 1990;  346(6283) 425-434
    CrossrefPubMedGoogle Scholar
  • 49 Spragg D D, Alford D R, Greferath R et al.. Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system.  Proc Natl Acad Sci U S A. 1997;  94(16) 8795-8800
    CrossrefPubMedGoogle Scholar
  • 50 Kiely J M, Cybulsky M I, Luscinskas F W, Gimbrone Jr M A. Immunoselective targeting of an anti-thrombin agent to the surface of cytokine-activated vascular endothelial cells.  Arterioscler Thromb Vasc Biol. 1995;  15(8) 1211-1218
    PubMedGoogle Scholar
  • 51 Kuijpers T W, Raleigh M, Kavanagh T et al.. Cytokine-activated endothelial cells internalize E-selectin into a lysosomal compartment of vesiculotubular shape. A tubulin-driven process.  J Immunol. 1994;  152(10) 5060-5069
    PubMedGoogle Scholar
  • 52 Straley K S, Green S A. Rapid transport of internalized P-selectin to late endosomes and the TGN: roles in regulating cell surface expression and recycling to secretory granules.  J Cell Biol. 2000;  151(1) 107-116
    CrossrefPubMedGoogle Scholar
  • 53 von Asmuth E J, Smeets E F, Ginsel L A, Onderwater J J, Leeuwenberg J F, Buurman W A. Evidence for endocytosis of E-selectin in human endothelial cells.  Eur J Immunol. 1992;  22(10) 2519-2526
    CrossrefPubMedGoogle Scholar
  • 54 Kessner S, Krause A, Rothe U, Bendas G. Investigation of the cellular uptake of E-Selectin-targeted immunoliposomes by activated human endothelial cells.  Biochim Biophys Acta. 2001;  1514(2) 177-190
    CrossrefPubMedGoogle Scholar
  • 55 Kok R J, Everts M, Asgeirsdóttir S A, Meijer D K, Molema G. Cellular handling of a dexamethasone-anti-E-selectin immunoconjugate by activated endothelial cells: comparison with free dexamethasone.  Pharm Res. 2002;  19(11) 1730-1735
    CrossrefPubMedGoogle Scholar
  • 56 Harari O A, Wickham T J, Stocker C J et al.. Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin.  Gene Ther. 1999;  6(5) 801-807
    CrossrefPubMedGoogle Scholar
  • 57 Lindner J R, Song J, Christiansen J, Klibanov A L, Xu F, Ley K. Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin.  Circulation. 2001;  104(17) 2107-2112
    CrossrefPubMedGoogle Scholar
  • 58 Kelly K A, Allport J R, Tsourkas A, Shinde-Patil V R, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle.  Circ Res. 2005;  96(3) 327-336
    CrossrefPubMedGoogle Scholar
  • 59 Keelan E T, Harrison A A, Chapman P T, Binns R M, Peters A M, Haskard D O. Imaging vascular endothelial activation: an approach using radiolabeled monoclonal antibodies against the endothelial cell adhesion molecule E-selectin.  J Nucl Med. 1994;  35(2) 276-281
    PubMedGoogle Scholar
  • 60 Lindner J R, Klibanov A L, Ley K. Targeting inflammation. In: Muzykantov VR, Torchilin VP Biomedical Aspects of Drug Targeting. Boston, MA; Kluwer Academic Publications 2003: 149-172
    Google Scholar
  • 61 Bonaventura J, Gow A. NO and superoxide: opposite ends of the seesaw in cardiac contractility.  Proc Natl Acad Sci U S A. 2004;  101(47) 16403-16404
    CrossrefPubMedGoogle Scholar
  • 62 Christofidou-Solomidou M, Muzykantov V R. Antioxidant strategies in respiratory medicine.  Treat Respir Med. 2006;  5(1) 47-78
    CrossrefPubMedGoogle Scholar
  • 63 Cai H, Griendling K K, Harrison D G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases.  Trends Pharmacol Sci. 2003;  24(9) 471-478
    CrossrefPubMedGoogle Scholar
  • 64 McCord J M. Superoxide dismutase in aging and disease: an overview.  Methods Enzymol. 2002;  349 331-341
    PubMedGoogle Scholar
  • 65 Kinnula V L, Crapo J D. Superoxide dismutases in the lung and human lung diseases.  Am J Respir Crit Care Med. 2003;  167(12) 1600-1619
    CrossrefPubMedGoogle Scholar
  • 66 Beckman J S, Minor Jr R L, White C W, Repine J E, Rosen G M, Freeman B A. Superoxide dismutase and catalase conjugated to polyethylene glycol increases endothelial enzyme activity and oxidant resistance.  J Biol Chem. 1988;  263(14) 6884-6892
    PubMedGoogle Scholar
  • 67 Giri S N, Misra H P. Fate of superoxide dismutase in mice following oral route of administration.  Med Biol. 1984;  62(5) 285-289
    PubMedGoogle Scholar
  • 68 Corvo M L, Boerman O C, Oyen W J et al.. Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. II. In vivo fate in a rat model of adjuvant arthritis.  Biochim Biophys Acta. 1999;  1419(2) 325-334
    CrossrefPubMedGoogle Scholar
  • 69 Fujita T, Nishikawa M, Tamaki C, Takakura Y, Hashida M, Sezaki H. Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharide derivatives.  J Pharmacol Exp Ther. 1992;  263(3) 971-978
    PubMedGoogle Scholar
  • 70 Freeman B A, Young S L, Crapo J D. Liposome-mediated augmentation of superoxide dismutase in endothelial cells prevents oxygen injury.  J Biol Chem. 1983;  258(20) 12534-12542
    PubMedGoogle Scholar
  • 71 Day B J, Shawen S, Liochev S I, Crapo J D. A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury, in vitro.  J Pharmacol Exp Ther. 1995;  275(3) 1227-1232
    PubMedGoogle Scholar
  • 72 Duann P, Datta P K, Pan C, Blumberg J B, Sharma M, Lianos E A. Superoxide dismutase mimetic preserves the glomerular capillary permeability barrier to protein.  J Pharmacol Exp Ther. 2006;  316(3) 1249-1254
    CrossrefPubMedGoogle Scholar
  • 73 Tamura Y, Chi L G, Driscoll Jr E M et al.. Superoxide dismutase conjugated to polyethylene glycol provides sustained protection against myocardial ischemia/reperfusion injury in canine heart.  Circ Res. 1988;  63(5) 944-959
    PubMedGoogle Scholar
  • 74 Igarashi R, Hoshino J, Ochiai A, Morizawa Y, Mizushima Y. Lecithinized superoxide dismutase enhances its pharmacologic potency by increasing its cell membrane affinity.  J Pharmacol Exp Ther. 1994;  271(3) 1672-1677
    PubMedGoogle Scholar
  • 75 Koo D D, Welsh K I, West N E et al.. Endothelial cell protection against ischemia/reperfusion injury by lecithinized superoxide dismutase.  Kidney Int. 2001;  60(2) 786-796
    CrossrefPubMedGoogle Scholar
  • 76 Ishihara T, Tanaka K, Tasaka Y et al.. Therapeutic effect of lecithinized superoxide dismutase against colitis.  J Pharmacol Exp Ther. 2009;  328(1) 152-164
    CrossrefPubMedGoogle Scholar
  • 77 Lee S, Murthy N. Targeted delivery of catalase and superoxide dismutase to macrophages using folate.  Biochem Biophys Res Commun. 2007;  360(1) 275-279
    CrossrefPubMedGoogle Scholar
  • 78 Gow A, Ischiropoulos H. Super-SOD: superoxide dismutase chimera fights off inflammation.  Am J Physiol Lung Cell Mol Physiol. 2003;  284(6) L915-L916
    PubMedGoogle Scholar
  • 79 Bonder C S, Knight D, Hernandez-Saavedra D, McCord J M, Kubes P. Chimeric SOD2/3 inhibits at the endothelial-neutrophil interface to limit vascular dysfunction in ischemia-reperfusion.  Am J Physiol Gastrointest Liver Physiol. 2004;  287(3) G676-G684
    CrossrefPubMedGoogle Scholar
  • 80 Gao B, Flores S C, Leff J A, Bose S K, McCord J M. Synthesis and anti-inflammatory activity of a chimeric recombinant superoxide dismutase: SOD2/3.  Am J Physiol Lung Cell Mol Physiol. 2003;  284(6) L917-L925
    PubMedGoogle Scholar
  • 81 Grey M, Yainoy S, Prachayasittikul V, Bülow L. A superoxide dismutase-human hemoglobin fusion protein showing enhanced antioxidative properties.  FEBS J. 2009;  276(21) 6195-6203
    CrossrefPubMedGoogle Scholar
  • 82 Lu M, Gong X, Lu Y, Guo J, Wang C, Pan Y. Molecular cloning and functional characterization of a cell-permeable superoxide dismutase targeted to lung adenocarcinoma cells. Inhibition cell proliferation through the Akt/p27kip1 pathway.  J Biol Chem. 2006;  281(19) 13620-13627
    CrossrefPubMedGoogle Scholar
  • 83 Jiang J, Kurnikov I, Belikova N A et al.. Structural requirements for optimized delivery, inhibition of oxidative stress, and antiapoptotic activity of targeted nitroxides.  J Pharmacol Exp Ther. 2007;  320(3) 1050-1060
    CrossrefPubMedGoogle Scholar
  • 84 Nishikawa M, Hashida M, Takakura Y. Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis.  Adv Drug Deliv Rev. 2009;  61(4) 319-326
    CrossrefPubMedGoogle Scholar
  • 85 Muzykantov V R, Christofidou-Solomidou M, Balyasnikova I et al.. Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs.  Proc Natl Acad Sci U S A. 1999;  96(5) 2379-2384
    CrossrefPubMedGoogle Scholar
  • 86 Christofidou-Solomidou M, Scherpereel A, Wiewrodt R et al.. PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress.  Am J Physiol Lung Cell Mol Physiol. 2003;  285(2) L283-L292
    CrossrefPubMedGoogle Scholar
  • 87 Shuvaev V V, Dziubla T, Wiewrodt R, Muzykantov V R. Streptavidin-biotin crosslinking of therapeutic enzymes with carrier antibodies: nanoconjugates for protection against endothelial oxidative stress.  Methods Mol Biol. 2004;  283 3-19
    PubMedGoogle Scholar
  • 88 Shuvaev V V, Christofidou-Solomidou M, Bhora F et al.. Targeted detoxification of selected reactive oxygen species in the vascular endothelium.  J Pharmacol Exp Ther. 2009;  331(2) 404-411
    CrossrefPubMedGoogle Scholar
  • 89 Kozower B D, Christofidou-Solomidou M, Sweitzer T D et al.. Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury.  Nat Biotechnol. 2003;  21(4) 392-398
    CrossrefPubMedGoogle Scholar
  • 90 Shuvaev V V, Tliba S, Nakada M, Albelda S M, Muzykantov V R. Platelet-endothelial cell adhesion molecule-1-directed endothelial targeting of superoxide dismutase alleviates oxidative stress caused by either extracellular or intracellular superoxide.  J Pharmacol Exp Ther. 2007;  323(2) 450-457
    CrossrefPubMedGoogle Scholar
  • 91 Muro S, Mateescu M, Gajewski C, Robinson M, Muzykantov V R, Koval M. Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins.  Am J Physiol Lung Cell Mol Physiol. 2006;  290(5) L809-L817
    CrossrefPubMedGoogle Scholar
  • 92 Muro S, Gajewski C, Koval M, Muzykantov V R. ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs.  Blood. 2005;  105(2) 650-658
    CrossrefPubMedGoogle Scholar
  • 93 Dziubla T D, Karim A, Muzykantov V R. Polymer nanocarriers protecting active enzyme cargo against proteolysis.  J Control Release. 2005;  102(2) 427-439
    CrossrefPubMedGoogle Scholar
  • 94 Simone E A, Dziubla T D, Arguiri E et al.. Loading PEG-catalase into filamentous and spherical polymer nanocarriers.  Pharm Res. 2009;  26(1) 250-260
    CrossrefPubMedGoogle Scholar
  • 95 Dziubla T D, Shuvaev V V, Hong N K et al.. Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies.  Biomaterials. 2008;  29(2) 215-227
    CrossrefPubMedGoogle Scholar
  • 96 Esmon C T. Inflammation and thrombosis.  J Thromb Haemost. 2003;  1(7) 1343-1348
    CrossrefPubMedGoogle Scholar
  • 97 Bode C, Meinhardt G, Runge M S et al.. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation.  Circulation. 1991;  84 805-813
    PubMedGoogle Scholar
  • 98 Runge M S, Quertermous T, Zavodny P J et al.. A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.  Proc Natl Acad Sci U S A. 1991;  88(22) 10337-10341
    CrossrefPubMedGoogle Scholar
  • 99 Waugh J M, Kattash M, Li J et al.. Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model.  Proc Natl Acad Sci U S A. 1999;  96(3) 1065-1070
    CrossrefPubMedGoogle Scholar
  • 100 Topol E J, Byzova T V, Plow E F. Platelet GPIIb-IIIa blockers.  Lancet. 1999;  353(9148) 227-231
    CrossrefPubMedGoogle Scholar
  • 101 Muzykantov V R, Barnathan E S, Atochina E N, Kuo A, Danilov S M, Fisher A B. Targeting of antibody-conjugated plasminogen activators to the pulmonary vasculature.  J Pharmacol Exp Ther. 1996;  279(2) 1026-1034
    PubMedGoogle Scholar
  • 102 Murciano J C, Harshaw D W, Ghitescu L, Danilov S M, Muzykantov V R. Vascular immunotargeting to endothelial surface in a specific macrodomain in alveolar capillaries.  Am J Respir Crit Care Med. 2001;  164(7) 1295-1302
    PubMedGoogle Scholar
  • 103 Ding B S, Zhou Y J, Chen X Y et al.. Lung endothelium targeting for pulmonary embolism thrombolysis.  Circulation. 2003;  108(23) 2892-2898
    CrossrefPubMedGoogle Scholar
  • 104 Muro S, Cui X, Gajewski C, Murciano J C, Muzykantov V R, Koval M. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress.  Am J Physiol Cell Physiol. 2003;  285(5) C1339-C1347
    CrossrefPubMedGoogle Scholar
  • 105 Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.  Crit Care Med. 2003;  31(4, suppl) S213-S220
    CrossrefPubMedGoogle Scholar
  • 106 Levi M, Schultz M. The inflammation-coagulation axis as an important intermediate pathway in acute lung injury.  Crit Care. 2008;  12(2) 144
    CrossrefPubMedGoogle Scholar
  • 107 Wu S Q, Aird W C. Thrombin, TNF-alpha, and LPS exert overlapping but nonidentical effects on gene expression in endothelial cells and vascular smooth muscle cells.  Am J Physiol Heart Circ Physiol. 2005;  289 H873-H885
    CrossrefPubMedGoogle Scholar
  • 108 Ding B S, Gottstein C, Grunow A et al.. Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature.  Blood. 2005;  106(13) 4191-4198
    CrossrefPubMedGoogle Scholar
  • 109 Stump D C, Lijnen H R, Collen D. Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator.  J Biol Chem. 1986;  261(36) 17120-17126
    PubMedGoogle Scholar
  • 110 Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator.  Nat Rev Mol Cell Biol. 2002;  3(12) 932-943
    CrossrefPubMedGoogle Scholar
  • 111 Liu J N, Gurewich V. Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK.  Biochemistry. 1992;  31(27) 6311-6317
    CrossrefPubMedGoogle Scholar
  • 112 Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin.  J Biol Chem. 1986;  261(8) 3486-3489
    PubMedGoogle Scholar
  • 113 Yang W P, Goldstein J, Procyk R, Matsueda G R, Shaw S Y. Design and evaluation of a thrombin-activable plasminogen activator.  Biochemistry. 1994;  33 606-612
    CrossrefPubMedGoogle Scholar
  • 114 Ding B S, Hong N, Murciano J C et al.. Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature.  Blood. 2008;  111(4) 1999-2006
    CrossrefPubMedGoogle Scholar
  • 115 Ding B S, Hong N K, Christofidou-Solomidou M et al.. Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation.  Am J Respir Crit Care Med. 2009;  180(3) 247-256
    CrossrefPubMedGoogle Scholar
  • 116 Wang Y X, Wu C, Vincelette J et al.. Amplified anticoagulant activity of tissue factor-targeted thrombomodulin: in-vivo validation of a tissue factor-neutralizing antibody fused to soluble thrombomodulin.  Thromb Haemost. 2006;  96(3) 317-324
    PubMedGoogle Scholar

Vladimir R MuzykantovM.D. 

IFEM, University of Pennsylvania Medical Center

1 John Morgan Building, 3620 Hamilton Walk, Philadelphia, PA 19104-6068

Email: muzykant@mail.med.upenn.edu

      >